163 related articles for article (PubMed ID: 21285989)
1. Interval cancers in the NHS breast cancer screening programme in England, Wales and Northern Ireland.
Bennett RL; Sellars SJ; Moss SM
Br J Cancer; 2011 Feb; 104(4):571-7. PubMed ID: 21285989
[TBL] [Abstract][Full Text] [Related]
2. Screen detection of ductal carcinoma in situ and subsequent incidence of invasive interval breast cancers: a retrospective population-based study.
Duffy SW; Dibden A; Michalopoulos D; Offman J; Parmar D; Jenkins J; Collins B; Robson T; Scorfield S; Green K; Hall C; Liao XH; Ryan M; Johnson F; Stevens G; Kearins O; Sellars S; Patnick J
Lancet Oncol; 2016 Jan; 17(1):109-14. PubMed ID: 26655422
[TBL] [Abstract][Full Text] [Related]
3. Annual mammographic screening to reduce breast cancer mortality in women from age 40 years: long-term follow-up of the UK Age RCT.
Duffy S; Vulkan D; Cuckle H; Parmar D; Sheikh S; Smith R; Evans A; Blyuss O; Johns L; Ellis I; Sasieni P; Wale C; Myles J; Moss S
Health Technol Assess; 2020 Oct; 24(55):1-24. PubMed ID: 33141657
[TBL] [Abstract][Full Text] [Related]
4. Mammography screening for breast cancer in Copenhagen April 1991-March 1997. Mammography Screening Evaluation Group.
Lynge E
APMIS Suppl; 1998; 83():1-44. PubMed ID: 9850674
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of mammographic surveillance services in women aged 40-49 years with a moderate family history of breast cancer: a single-arm cohort study.
Duffy SW; Mackay J; Thomas S; Anderson E; Chen TH; Ellis I; Evans G; Fielder H; Fox R; Gui G; Macmillan D; Moss S; Rogers C; Sibbering M; Wallis M; Warren R; Watson E; Whynes D; Allgood P; Caunt J
Health Technol Assess; 2013 Mar; 17(11):vii-xiv, 1-95. PubMed ID: 23489892
[TBL] [Abstract][Full Text] [Related]
6. Calculating appropriate target cancer detection rates and expected interval cancer rates for the UK NHS Breast Screening Programme. Interval Cancer Working Group.
Moss S; Blanks R
J Epidemiol Community Health; 1998 Feb; 52(2):111-5. PubMed ID: 9578858
[TBL] [Abstract][Full Text] [Related]
7. Interval cancer rates in the Irish national breast screening programme.
O'Brien KM; Dwane F; Kelleher T; Sharp L; Comber H
J Med Screen; 2015 Sep; 22(3):136-43. PubMed ID: 25917389
[TBL] [Abstract][Full Text] [Related]
8. The Scottish breast screening programme's experience of monitoring interval cancers.
Everington D; Gilbert FJ; Tyack C; Warner J
J Med Screen; 1999; 6(1):21-7. PubMed ID: 10321366
[TBL] [Abstract][Full Text] [Related]
9. Changes in incidence of and mortality from breast cancer in England and Wales since introduction of screening. United Kingdom Association of Cancer Registries.
Quinn M; Allen E
BMJ; 1995 Nov; 311(7017):1391-5. PubMed ID: 8520272
[TBL] [Abstract][Full Text] [Related]
10. Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial.
Menon U; Gentry-Maharaj A; Burnell M; Ryan A; Kalsi JK; Singh N; Dawnay A; Fallowfield L; McGuire AJ; Campbell S; Skates SJ; Parmar M; Jacobs IJ
Health Technol Assess; 2023 May; ():1-81. PubMed ID: 37183782
[TBL] [Abstract][Full Text] [Related]
11. Is the three year breast screening interval too long? Occurrence of interval cancers in NHS breast screening programme's north western region.
Woodman CB; Threlfall AG; Boggis CR; Prior P
BMJ; 1995 Jan; 310(6974):224-6. PubMed ID: 7866124
[TBL] [Abstract][Full Text] [Related]
12. Effect of population breast screening on breast cancer mortality to 2005 in England and Wales: A nested case-control study within a cohort of one million women.
Johns LE; Swerdlow AJ; Moss SM
J Med Screen; 2018 Jun; 25(2):76-81. PubMed ID: 28675954
[TBL] [Abstract][Full Text] [Related]
13. The age-specific differences in histopathological tumor characteristics and TNM classification of breast carcinomas in Quality assured mamma diagnostic (QuaMaDi) program in the state of Schleswig-Holstein in Germany.
Kramp LJ; Mathiak M; Behrens HM; Schäfer FW; van Mackelenbergh M; Röcken C
J Cancer Res Clin Oncol; 2022 Feb; 148(2):387-400. PubMed ID: 34705105
[TBL] [Abstract][Full Text] [Related]
14. [Tailored Breast Screening Trial (TBST)].
Paci E; Mantellini P; Giorgi Rossi P; Falini P; Puliti D;
Epidemiol Prev; 2013; 37(4-5):317-27. PubMed ID: 24293498
[TBL] [Abstract][Full Text] [Related]
15. Mammography screening: A major issue in medicine.
Autier P; Boniol M
Eur J Cancer; 2018 Feb; 90():34-62. PubMed ID: 29272783
[TBL] [Abstract][Full Text] [Related]
16. What should the detection rates of cancers be in breast screening programmes?
Duffy SW; Gabe R
Br J Cancer; 2005 Feb; 92(3):597-600. PubMed ID: 15668711
[TBL] [Abstract][Full Text] [Related]
17. Results from 10 years of breast screening in Wales.
Fielder H; Rogers C; Gower-Thomas K; Monypenny I; Dallimore N; Brook D; Greening S
J Med Screen; 2001; 8(1):21-3. PubMed ID: 11373845
[TBL] [Abstract][Full Text] [Related]
18. Confidence intervals and interval cancers ... needles and haystacks?
Kee F; Gorman D; Odling-Smee W
Public Health; 1992 Jan; 106(1):29-35. PubMed ID: 1603914
[TBL] [Abstract][Full Text] [Related]
19. The National Breast Screening Programme: the first 5,000 women screened in Northern Ireland.
O'Doherty AJ; Crothers JG; Majury CW
Ulster Med J; 1991 Oct; 60(2):150-3. PubMed ID: 1785147
[TBL] [Abstract][Full Text] [Related]
20. Interval breast cancers: absolute and proportional incidence and blinded review in a community mammographic screening program.
Carbonaro LA; Azzarone A; Paskeh BB; Brambilla G; Brunelli S; Calori A; Caumo F; Malerba P; Menicagli L; Sconfienza LM; Vadalà G; Brambilla G; Fantini L; Ciatto S; Sardanelli F
Eur J Radiol; 2014 Feb; 83(2):e84-91. PubMed ID: 24369953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
